• Antengene presented preclinical results for autoimmune disease candidate ATG-207 at the 2026 American College of Rheumatology annual meeting.
• ATG-207 suppressed harmful T-cell activity and promoted regulatory immune cells in laboratory studies, supporting its potential to restore immune tolerance.
• Mouse studies showed efficacy across autoimmune disease models; ATG-207 and its mouse surrogate were well tolerated in toxicology studies.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Antengene Corporation Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202611112211PR_NEWS_USPR_____CN96035) on November 12, 2026, and is solely responsible for the information contained therein.